DOCSLIB.ORG

Fluffy Luminal Surface of the Non-Stenotic Culprit Coronary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluffy Luminal Surface of the Non-Stenotic Culprit Coronary Advance Publication by J-STAGE Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Fluffy Luminal Surface of the Non-Stenotic Culprit Coronary Artery in Patients With Acute Coronary Syndrome – An Angioscopic Study – Yasumi Uchida, MD; Yasuto Uchida, MD; Takeshi Sakurai, MD; Masahito Kanai, MD; Seiichiro Shirai, MD; Tomomitsu Oshima, MD; Atsushi Koga, MD; Akimasa Matsuyama, MD; Tsuyoshi Tabata, PhD Background: Approximately 15% of acute coronary syndrome (ACS) cases have no significant coronary ste- nosis. Mechanisms underlying the attacks are, however, unknown. Methods and Results: The clinical study had 254 patients with ACS; 38 patients (31 females and 7 males; aged 51.0±8.0 years) had no significant coronary stenosis on angiography. They underwent a dye-staining angioscopy of the suspected culprit coronary artery using Evans blue, which selectively stains fibrin and damaged endothelial cells. A fluffy coronary luminal surface was observed in the suspected culprit artery in all 38 patients. The fluffy luminal surface was stained blue with Evans blue. In animal experiments involving 5 beagles, 10% hydrogen peroxide solution was injected into the iliac arteries to damage endothelial cells, which was then followed by blood reperfusion, and then the artery was examined by intravascular microscopy and histology. In the beagles, the arterial segment, where the thrombus had been formed, exhibited a fluffy luminal surface after a washout of the thrombus, and the surface was stained blue. Histologically, the fluffy surfaces were composed of damaged endothelial cells attached by multiple fibrin threads and platelets. Conclusions: It was considered that the coronary segment exhibiting a fluffy luminal surface was the culprit lesion and that the fluffy surface was caused by residual thrombi after dispersion of an occlusive thrombus, which had formed on the damaged endothelial cells. Key Words: Acute coronary syndrome; Dye-staining angioscopy; Endothelial cell damages; Fibrin and platelets; Fluffy coronary luminal surface cute coronary syndrome (ACS) is generally caused by nary stenosis frequently exhibit impaired coronary flow, as an occlusive thrombus formed on a disrupted plaque. assessed angiographically, coronary microvascular dysfunc- A There are ACS patients in whom significant coro- tion was proposed as a causative mechanism for the attacks; nary stenosis (>50% luminal diameter stenosis) is not ob- however, definitive evidence has not yet been demonstrated served angiographically. Nesto et al reported that 13% of to support this.5 patients with unstable angina (UA) had no significant coro- Angioscopy has been clinically used for imaging the nary stenosis on angiography.1 Hochman et al reported that changes in the coronary artery.6–13 During angioscopic exam- 15% of patients with UA and non-ST elevation myocardial ination of the culprit coronary arteries in patients with ACS, infarction (NSTEMI) had no significant coronary stenosis.2 the authors of the present study noticed the culprit but non- Similar findings have been reported by others.3,4 stenotic coronary artery had a fluffy luminal surface in patients As patients with UA/NSTEMI without significant coro- with ACS. Therefore, the incidence and mechanism(s) of Received May 7, 2010; revised manuscript received June 22, 2010; accepted June 28, 2010; released online September 4, 2010 Time for primary review: 19 days Japan Foundation for Cardiovascular Research, Funabashi (Y.U.); Cardiovascular Center, Toho University Medical Center Sakura Hospital, Sakura (Y.U., T.S., M.K.); Department of Cardiology, Tokyo Jikei University School of Medicine, Tokyo (Y.U., A.K., A.M.); Department of Cardiology, Toho University Medical Center Ohmori Hospital, Tokyo (Yasuto Uchida); Department of Cardiology, Funabashi-Futawa Hospital, Funabashi (S.S., T.O.); and Clinical Physiology, Toho University Medical Center Sakura Hospital, Sakura (T.T.), Japan Mailing address: Yasumi Uchida, MD, Japan Foundation for Cardiovascular Research, 2-30-17 Narashinodai, Funabashi 274-0063, Japan. E-mail: [email protected] ISSN-1346-9843 doi: 10.1253/circj.CJ-10-0422 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: [email protected] Advance Publication by J-STAGE UCHIDA Y et al. Figure 1. A smooth surfaced white plaque in the left anterior descending artery, demonstrated for comparison with a fluffy luminal surface. A 60-year-old male with stable angina. (A) Angiogram of the left coronary artery showing a stenosis in the middle segment of the left anterior descending artery (arrow B). (B) Angioscopic image of a white plaque (arrow) that corre- sponded to the stenotic portion in (A). The surface of the plaque was smooth and sharply margined. Figure 2. Fluffy luminal surface of the left anterior descending artery. A 51-year-old female with unstable angina (UA). (A) An- giogram of the left coronary artery. Arrow: The middle segment of the left anterior descending artery observed by angioscopy is shown by the arrow B. The margin of the segment was irregular. (B-1) Angioscopic image of the same segment. The entire circumference of the luminal surface was fluffy (diffuse type) and white (arrows). Arrowhead: guidewire. (B-2) The fluffy surface was diffusely stained blue with Evans blue (arrow). this angioscopic changes were examined. Tokyo, Japan), a 5-F angioscope (VecMover; Clinical Supply Co, Gifu, Japan) and a color chilled charge-coupled device (CCD) camera (CSVEC-10; Clinical Supply). Before carry- Methods ing out the angioscopic examination, the white balance of Clinical Study the camera was adjusted for color correction. The system Subjects From 1 April 2000 to 31 March 2009, 254 has been approved for clinical use by the Japanese Ministry patients with ACS underwent coronary angioscopy at our of Health, Labor and Welfare. Details of this system are hospitals. Of these patients, 38 (31 females and 7 males; described elsewhere.11,14 mean ± SD age, 51.0±8.0 years; 25 with UA, 11 with NSTEMI Conventional Angioscopy Coronary angioscopy was car- and 2 with ST-elevation myocardial infarction (STEMI)) ried out at the Toho University Sakura Hospital (Sakura, had no significant stenosis of the suspected culprit coronary Japan) and Funabashi-Futawa Hospital (Funabashi, Japan) artery, whereas 216 (64 females and 152 males; age 60.0± with the approval of their Institutional Review Boards. All 7.1 years; 75 with UA, 40 with NSTEMI and 115 with patients in the present study provided their informed consent STEMI) had significant stenoses of the suspected culprit with regard to all the procedures followed herein. coronary arteries. All patients received heparin (5,000 IU iv) just before Coronary Angioscopy System The angioscopy system was the procedure and nitroglycerin (200μ g, ic) just before the composed of a light source (OTV-A; Olympus Corporation, coronary angiography. The diameter stenosis of the coronary Advance Publication by J-STAGE Fluffy Coronary Luminal Surface in ACS Figure 3. Diffuse and patchy types of the fluffy coronary luminal surface. (A-1) A diffuse type of the fluffy luminal surface before EB (arrows). (A-2) The same por- tion after EB. The fluffy portion was stained blue (arrows). Arrowheads in (A-1) and (A-2): guidewire. (B-1) A patchy type of fluffy luminal surface before EB (arrows). (B-2) The same portion after EB. The sur- face was stained blue in a patchy fashion (arrows). EB, Evans blue. artery was measured by TCS Symphony 2.02 (McKesson Co, Animal Experiments North Charleston, SC, USA), and expressed as a percentage. Animal experiments were performed not to produce an ACS After a coronary angiography of a culprit coronary artery model but to examine what happened when blood was per- was performed, which was suspected by electrocardiography, fused into the artery after diffuse endothelial cell damage. ultrasonic echocardiography and angiography, an angioscope Animal experiments were carried out at the Institute for was introduced into the artery. The balloon of the angioscope Animal Experiments of the Jikei University School of Medi- was inflated to stop the blood flow therein. The fiberscope cine (Tokyo). The protocols followed when conducting the incorporated into the angioscope was slowly advanced up experiments on animals were approved by the University to 7 cm distally to facilitate successive observations of the Administrative Panel on Laboratory Animal Care. artery while displacing the blood by infusion of heparinized Five beagles were anesthetized with pentobarbital sodium saline solution (10 IU/ml) at a rate of 2 ml/s for 10–20 s (30 mg/kg, iv). The abdominal aorta below the renal arteries through the flash channel of the angioscope. and both right and left iliac arteries and their branches were To confirm the accurate location of the angioscope tip constricted with threads. One 8-F catheter and one 9-F cathe- (and accordingly the observed portion), the angioscopic and ter were introduced in retrograde fashion into the left and fluoroscopic images were displayed simultaneously on a tele- right iliac arteries, respectively. Subsequently, a saline solu- vision monitor. tion was infused at a rate of 20 ml/min through the left iliac Dye-Staining Coronary Angioscopy Evans blue is a blue artery into the right iliac artery. Next, a 9-F intravascular dye that had been used clinically for cardiac output measure- microscope, which enables observation of a target at up to ment for many years. Since 1995, this dye has been clinically x350 magnification, was introduced into the right iliac artery administered into the arterial system for staining damaged for observation. The 5 ml of 10% hydrogen peroxide solution endothelial cells and fibrin without obvious side effects.14,15 was then injected into the perfusion circuit to damage the Beneficial effects of this dye in the prevention of coronary endothelial cells, and the blood from the aorta was allowed to restenosis has been proven.16 drain into the right iliac artery by the loosening of the aortic Thirty-eight patients who had no significant stenosis of the occlusion.
Load more

Recommended publications
  • Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human Ntpdase1
    Hindawi Publishing Corporation Mediators of Inflammation Volume 2014, Article ID 547480, 8 pages http://dx.doi.org/10.1155/2014/547480 Research Article Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1 Joanna Lecka,1,2 Michel Fausther,1,2 Beat Künzli,3 and Jean Sévigny1,2 1 Departement´ de Microbiologie-Infectiologie et d’Immunologie, FacultedeM´ edecine,´ UniversiteLaval,Qu´ ebec,´ QC, Canada G1V 0A6 2 Centre de Recherche du CHU de Quebec,´ 2705 Boulevard Laurier, Local T1-49, Quebec,´ QC, Canada G1V 4G2 3 Department of Surgery, Klinikum Rechts der Isar, Technische Universitat¨ Munchen,¨ 81675 Munich, Germany Correspondence should be addressed to Jean Sevigny;´ [email protected] Received 12 May 2014; Accepted 21 July 2014; Published 11 August 2014 Academic Editor: Mireia Mart´ın-Satue´ Copyright © 2014 Joanna Lecka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), like other ectonucleotidases, controls extracellular nucleotide levels and consequently their (patho)physiological responses such as in thrombosis, inflammation, and cancer. Selective NTPDase1 inhibitors would therefore be very useful. We previously observed that ticlopidine in its prodrug form, which does not affect P2 receptor activity, inhibited the recombinant form of human NTPDase1 ( =14M). Here we tested whether ticlopidine can be used as a selective inhibitor of NTPDase1. We confirmed that ticlopidine inhibits NTPDase1 in different forms and in different assays. The ADPase activity of intact HUVEC as well as of COS-7 cells transfected with human NTPDase1 was strongly inhibited by 100 M ticlopidine, 99 and 86%, respectively.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs
    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
    [Show full text]
  • Preventive Medication Program
    PREVENTIVE MEDICATION PROGRAM Generics and Preferred Brands Drug List Starting July 1, 2021 Preventive medications are used to prevent certain conditions from developing, or to prevent a condition from coming back. These conditions include, but are not limited to, asthma, depression, diabetes, heart attack, high blood pressure, high cholesterol, osteoporosis, prenatal nutrient deficiency and stroke. About this drug list. Your cost-share for preventive generic and This is a list of the most commonly prescribed generic preferred brand medications. and preferred brand medications that are part of Not all plans offer the same cost-share for their Cigna’s preventive medication program as of July preventive medication program. For example, some 1, 2021.1,2 This drug list is updated often so it isn’t a plans may require you to pay a copay, coinsurance complete list of medications. Also, your specific plan’s and/or deductible for preventive generic and preferred preventive medication program may not include all brand medications; other plans may not. of these medications and/or conditions. Log in to the Log into the myCigna App or myCigna.com and use myCigna® App or myCigna.com, or check your plan the Price a Medication tool to see how much your materials, to see all of the medications included in your medication may cost you at the different pharmacies in plan’s preventive medication program and how much your plan’s network.3 they cost. Here’s some helpful information about this drug list: › Medications are listed alphabetically by condition. › Brand-name medications are capitalized and generic medications are lowercase.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Preventive Generic Drugs Listing
    2017 PREVENTIVE DRUG LIST Preventive medications are used for the prevention of conditions such as high blood pressure, high cholesterol, diabetes, asthma, osteoporosis, heart attack, stroke and prenatal nutrient deficiency. You may not have to pay a copay, a coinsurance (the percentage you pay after you meet your deductible) and/or a deductible (the amount you pay before your plan starts to pay) for preventive medications. Please check your plan’s prescription drug list and This list is subject to change and may not include all plan documents to understand how your plan covers preventive medications that your plan covers. Please preventive medications. You can refer to myCigna.com refer to your plan’s prescription drug list for a complete for a complete and up-to-date drug listing for your plan. and up-to-date drug listing. You can also use the Prescription Drug Price Quote tool on myCigna.com to view and compare drug prices. The following is a list of generic and brand-name If you have questions preventive medications, arranged by type of condition. Please call the toll-free number on the back of Talk with your doctor when choosing the preventive your Cigna ID card. We’re here to help. medication that is right for you. Also talk with your doctor about available generic preventive medications (listed as uncapitalized medications and/or in parentheses). Generic medications have the same active ingredients, dosage form, quality and strength, as their brand-name counterparts and may provide additional savings for you. Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates.
    [Show full text]
  • MEDICINE to TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What Are These Medicines U
    PATIENT INFORMATION LEAFLET MEDICINE TO TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What are these medicines used for? Medicine Purpose of medicine Brand Names This medicine makes blood less sticky to reduce the chance of blood forming Aspirin Cardiprin® clots which will lead to stroke or heart Disprin® attack. This medicine makes the blood less Dipyridamole sticky to reduce the chance of stroke. It Persantin® is used together with aspirin. These medicines make your blood less Clopidogrel (Plavix®) Clopidogrel sticky to reduce chance of stroke or Ticlopidine (Ticlid®), Ticlopidine heart attack. They can be used alone or together with aspirin. 2. How should I take the medicines? • Do not stop taking your medicines without checking with your doctors. • If you miss a dose, take the missed dose as soon as you remember. If it is almost time for your next dose, take only the usual dose. Do not double your dose or use extra medicine to make up for the missed dose. • You should take your medicine after a meal to prevent stomach upset. • How you take aspirin depends on the brand and type of aspirin the doctor gives you: o For tablets which can be chewed: Take with food or glass of water or milk These tablets may be chewed or swallowed whole The solution may also be used as a gargle. Please check with your pharmacist on how to use it as a gargle. o For tablets which enteric coated: Enteric coated forms of aspirin reduce stomach upset that is caused by the medicine Take with a glass of water after food.
    [Show full text]
  • Clinical Update
    Atualização Clínica Antiagregantes Plaquetários na Prevenção Primária e Secundária de Eventos Aterotrombóticos Platelet Antiaggregants in Primary and Secondary Prevention of Atherothrombotic Events Marcos Vinícius Ferreira Silva1, Luci Maria SantAna Dusse1, Lauro Mello Vieira, Maria das Graças Carvalho1 Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais1, Belo Horizonte, MG – Brasil Resumo prevenção primária e secundária de tais eventos. Os fatores A aterotrombose e suas complicações correspondem, de risco associados ao desenvolvimento desses eventos hoje, à principal causa de mortalidade no mundo todo, estão intimamente associados à exacerbação da ativação e sua incidência encontra-se em franca expansão. plaquetária que, por sua vez, favorece a formação de As plaquetas desempenham um papel essencial na agregados plaquetários e geração de trombina, resultando patogênese dos eventos aterotrombóticos, justificando a em trombos ricos em plaquetas (trombos brancos). Dessa utilização dos antiagregantes plaquetários na prevenção forma, o uso de antiagregantes plaquetários tem sido dos mesmos. Desse modo, é essencial que se conheça o benéfico na prevenção primária e secundária de eventos perfil de eficácia e segurança desses fármacos em prevenção mediados por trombos. primária e secundária de eventos aterotrombóticos. Dentro As características dos principais antiagregantes plaquetários desse contexto, a presente revisão foi realizada com o utilizados na prática clínica e em fase de estudos estão objetivo de descrever e sintetizar os resultados dos principais descritos na Tabela 13-9, e as proteínas de membrana com as ensaios, envolvendo a utilização de antiagregantes nos dois quais eles interagem e as vias metabólicas nas quais atuam níveis de prevenção, e avaliando a eficácia e os principais são ilustrados Figura 110.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • RESEARCH PROTOCOL Role of CYP2B6 Polymorphisms In
    RESEARCH PROTOCOL Role of CYP2B6 polymorphisms in ketamine metabolism and clearance Evan D. Kharasch, M.D., Ph.D. Russell D. and Mary B. Shelden Professor of Anesthesiology Director, Division of Clinical and Translational Research Washington University School of Medicine Department of Anesthesiology 660 S. Euclid Ave., Campus Box 8054 St. Louis, Mo. 63110 Voice: (314) 362-8796 Fax: (314) 747-3371 E-mail: [email protected] Original Version: July 9, 2013 2 1. SYNOPSIS Study Title Role of CYP2B6 polymorphisms in ketamine metabolism and clearance Objective To determine the effects of cytochrome P4502B6 (CYP2B6) genetic variants on ketamine metabolism and clearance Study Design Single-center, open label, single-session study to evaluate ketamine pharmaco- kinetics in subjects with known CYP2B6 genotype Study Period Planned enrollment duration: Approximately 3 months. Planned study duration: 1 day per subject Number of Patients Approximately 40 healthy volunteers identified by CYP2B6 genotyping by HRPO-approved screening Inclusion and Inclusion Criteria Exclusion Criteria a) 18-50 yr old b) CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype c) Good general health with no remarkable medical conditions d) BMI < 33 e) Provide informed consent Exclusion Criteria a) Known history of liver or kidney disease b) Use of prescription or non-prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6 c) Females who are pregnant or nursing d) Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction) e) Direct physical access to and routine handling of addicting drugs in the regular course of duty (a routine exclusion from studies of drugs with addiction potential) Study Medication Subjects will be studied on one occasion at Washington University in St.
    [Show full text]
  • Therapeutic Class Overview Platelet Inhibitors
    Therapeutic Class Overview Platelet Inhibitors Therapeutic Class • Overview/Summary: Platelet inhibitors play a major role in the management of cardiovascular, cerebrovascular, and peripheral vascular diseases. The agents in the class are Food and Drug Administration (FDA)-approved for a variety of indications including treatment and/or prevention of acute coronary syndromes, stroke/transient ischemic attack, and thrombocythemia. The platelet inhibitors are also indicated to prevent thrombosis in patients undergoing cardiovascular procedures and/or surgery. The platelet inhibitors exert their pharmacologic effects through several different mechanisms of action.1-8 The newest platelet inhibitor to be FDA-approved is vorapaxar (Zontivity®), which is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).7 Vorapaxar (Zontivity®), is the first in a new class of antiplatelet agents called protease-activated receptor-1 (PAR-1) antagonists. It is a competitive and selective antagonist of PAR-1, the major thrombin receptor on human platelets. It works by inhibiting thrombin-induced platelet aggregation and thus blood clot formation. In addition, vorapaxar is not a prodrug and does not require enzymatic conversion to become pharmacologically active, and is not subject to potential drug interactions associated with the other agents.7 Vorapaxar is available for once-daily dosing in combination with other antiplatelet agents (either clopidogrel
    [Show full text]
  • Summary of Product Characteristics
    Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT <invented name> 500 mg / 30 mg granules for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 500 mg acetylsalicylic acid and 30 mg pseudoephedrine hydrochloride Excipient with known effect: Each sachet contains 2 g sucrose. For the full list of excipients, see 6.1 3. PHARMACEUTICAL FORM Granules for oral suspension White to yellowish granules 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Symptomatic treatment of nasal congestion with cold-related pain and fever 4.2 Posology and method of administration Posology Adults and adolescents(16 years and older): The content of 1-2 sachets (corresponding to 500-1000 mg acetylsalicylic acid / 30-60 mg pseudoephedrine hydrochloride) If necessary, the single dose may be repeated at intervals of 4-8 hours. A maximum daily dose of 6 sachets (corresponding to 3000 mg acetylsalicylic acid / 180 mg pseudoephedrine hydrochloride) must not be exceeded. <invented name> must not be taken for more than 3 days without consulting a doctor. Paediatric population <invented name> is not recommended for use in children and adolescents aged under 16 years, unless on the advice of a doctor. Due to limited experience with <invented name> in children and adolescents a specified dose recommendation cannot be given. Where one of the symptoms predominates, treatment with mono therapy is more appropriate. Method of administration Oral use. <invented name> must be suspended in a glass of hot, but not boiling water. To
    [Show full text]